Osang Healthcare오상헬스케어
036220 · KOSDAQ · ₩036220 · 오상헬스케어
- Market cap
- ₩73B
- Enterprise value
- ₩49B
- P/E
- —
- P/B
- 0.3×
- Dividend yield
- 3.9%
- ROE
- −3.0%
- Net margin
- −8.8%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−65.1% from the high
₩5,010Today: ₩5,010 – ₩5,410₩14,600
Returns
- 1W−8.6%
- 1M−20.7%
- 3M−15.9%
- 6M−43.9%
- YTD−57.0%
- 1Y−61.0%
- Volume today
- 22,720
- 0.6× the 20-day average
- Traded today
- ₩115M
- Listed shares
- 14,309,416
- EPS (12 months)
- −₩591
- Earnings yield −11.6%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 35 of 100 (50 is a normal day for this stock).
- MomentumWeak-21% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Osang Healthcare stock overview
Osang Healthcare (오상헬스케어, KRX: 036220) is listed on KOSDAQ, in the Medical & precision devices sector. The company develops, manufactures and sells in vitro diagnostic (IVD) products that detect diseases using samples such as blood, body fluids and saliva, with the aim of making disease testing simple for everyone. Its shares closed at ₩5,090 on Oct 30, 2026, down 2.12% on the day, giving it a market value of ₩73B.
Key facts
- Market cap
- ₩73B
- Sector
- Medical & precision devices
- Latest price change
- −2.12%
- As of
- Oct 30, 2026
- Main business
- The company develops, manufactures and sells in vitro diagnostic (IVD) products that detect diseases using samples such as blood, body fluids and saliva, with the aim of making disease testing simple for everyone.
Quick answers about Osang Healthcare
- What does Osang Healthcare do?
- The company develops, manufactures and sells in vitro diagnostic (IVD) products that detect diseases using samples such as blood, body fluids and saliva, with the aim of making disease testing simple for everyone. Its product lines cover biochemical diagnostics (including self-blood glucose meters, POCT HbA1c meters and cholesterol meters), immunodiagnostics (such as the SelexOn analyzer and COVID-19 test kits) and molecular diagnostics based on real-time PCR, sold to users including pharmacies, clinics, hospitals and online medical services. Its main subsidiaries handle distribution in the United States and Brazil, and it sells in Korea, Europe, Asia, Africa and other overseas markets.
- What is the market cap of Osang Healthcare?
- The market capitalisation of Osang Healthcare was ₩73B at the close on Oct 30, 2026.
- Who are the largest shareholders of Osang Healthcare?
- According to the latest official filings, the largest reported holders are Oh Sang (57.67%, as of Apr 14, 2026); Ohsang Jayel (15.93%, as of Feb 17, 2025); National Pension Service (1.36%, as of Dec 31, 2025).
- When is the next earnings report from Osang Healthcare?
- Korean companies rarely announce results dates in advance. Based on when Osang Healthcare filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Osang Healthcare?
- Yes. The National Pension Service held 1.36% of Osang Healthcare shares as of Dec 31, 2025.
Company profile
The company develops, manufactures and sells in vitro diagnostic (IVD) products that detect diseases using samples such as blood, body fluids and saliva, with the aim of making disease testing simple for everyone. Its product lines cover biochemical diagnostics (including self-blood glucose meters, POCT HbA1c meters and cholesterol meters), immunodiagnostics (such as the SelexOn analyzer and COVID-19 test kits) and molecular diagnostics based on real-time PCR, sold to users including pharmacies, clinics, hospitals and online medical services. Its main subsidiaries handle distribution in the United States and Brazil, and it sells in Korea, Europe, Asia, Africa and other overseas markets.
Written by AI from the company's latest annual report.
- Korean name
- 오상헬스케어
- Themes
- Medical devices
- CEO
- 강철훈, 유병열(각자대표이사)
- Founded
- Apr 1996
- Listed
- Mar 2024
- Listed shares
- 14,309,416
- Fiscal year ends
- Month 12
- Website
- www.osanghc.com
Similar companies
- TSE131290 · ₩2.5T₩222,000−14.78%
- Kctech281820 · ₩1.7T₩87,500−10.26%
- Classys214150 · ₩1.7T₩26,200−2.24%
- Park Systems140860 · ₩1.5T₩219,500−3.94%
- DI003160 · ₩1.1T₩39,000−10.34%
- LivsMed491000 · ₩995B₩39,400−2.60%
- Seers458870 · ₩859B₩22,400−5.29%
- Curiox Biosystems445680 · ₩851B₩49,400−18.48%
Recent filings
See all- Half-year report (Jun 2026)Aug 14, 2026
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent DirectorsAug 11, 2026
- Quarterly report (Mar 2026)May 15, 2026
- Major sales or supply contractMay 13, 2026
- Insider shareholding reportMay 12, 2026
Titles in Korean until English translations are added.
Also known as: Osang Healthcare / 오상헬스케어 / 036220 / KRX:036220
Source: KRX statistical information